

MAY 1 2002

(Modified) PTO/SB/08A-B (10-96)

Approved for use through 10/31/99. OMB 0651-003

Substitute for form 1449A-B/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	09/729,478
Filing Date	December 4, 2000
First Named Inventor	Peter J. Kushner
Group Art Unit	1646
Examiner Name	E. Kemmerer
Attorney Docket Number	407T-896330US
Date Submitted	

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code (if known)			
CK	1	5,071,773	—	Evans	12-10-1991	—

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (if known)				
CK	2	WO	95/06754		The Regents of the University of California	09-03-1995	—	
↓	3	EP	0629697 A2		Eli Lilly and Co.	12-21-1994	—	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T
CK	4	Andersson et al., (1992) "Carcinogenic Effects of Adjuvant Tamoxifen Treatment and Radiotherapy for Early Breast Cancer" <i>Acta Oncologica</i> 31(2), 259-263.	
	5	Angel and Karin, (1991) "The Role of Jun, Fos and the AP-1 complex in cell-production and transformation." <i>Biochimica et Biophysica Acta</i> . 1072:129-157.	
	6	Anzai et al. (1989) "Stimulatory Effects of 4-Hydroxytamoxifen on Proliferation of Human Endometrial Adenocarcinoma Cells." <i>Cancer Res.</i> 49:2362-2365	
	7	Berry, et al., (1990) "Role of the two activating domains of the oestrogen receptor in the cell-type and promoter-context dependent agonistic activity of the anti-oestrogen 4-hydroxytamoxifen." <i>EMBO J.</i> 9(9), 2811-2818.	
	8	Bracke, et al., (1991) "Retinoic acid modulates both invasion and plasma membrane ruffling of MCF-7 human mammary carcinoma cells in vitro." <i>Br. J. Cancer</i> 63:867-872.	
	9	Dauvois, et al (1992) "Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover." <i>Proc. Natl. Acad. Sci. USA</i> 89:4037-4041.	
	10	Davis et al (1993) "Medical Hypothesis: Xenoestrogens as Preventable Causes of Breast Cancer." <i>Environmental Health Perspectives</i> , 101(5):372-377.	
		inhibits oestrogen receptor activity in human breast cancer derived cells. <i>EMBO J.</i> 10(8):2237-2245.	
	12	Dubik, et al. (1992) "Mechanism of estrogen activation of c-myc oncogene expression." <i>Oncogene</i> . 7:1587-1594.	

Examiner
Signature

Date

Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.